Revenues of $395.0 million, up 14.9% in Q4 on a reported basis Adjusted OIBDA of $120.6 million, up 9.4% in Q4 on a reported basis Q4 AFFO of $79.1 million; Operating Income of $50.5 million; Net income of $27.8 million
Quarterly dividend increased 4.6% to $46.4 million, payable March 31, 2015 Special dividend of $8.2 million payable March 31, 2015 NEW YORK , Feb.

OvaScience SM (NASDAQ: OVAS), a global life sciences company
focused on the discovery, development and commercialization of new
fertility treatments, today announced the Company has achieved its 2014
corporate goals to advance the AUGMENT SM , OvaPrime SM
and OvaTure SM treatments for patients in need of new
fertility treatment options.

OvaScience SM (NASDAQ: OVAS), a global life sciences company
focused on the discovery, development and commercialization of new
fertility treatments, announced today the closing of its previously
announced public offering of common stock, including the exercise in
full by the underwriters of their option to purchase an additional
345,000 shares of common stock at the public offering price of $50.00
per share.

OvaScience SM (NASDAQ: OVAS), a global life sciences company
focused on the discovery, development and commercialization of new
fertility treatments, announced today it has commenced an underwritten
public offering of up to $85 million of shares of its common stock.

OvaScience SM (NASDAQ: OVAS), a global life sciences company
focused on the discovery, development and commercialization of new
fertility treatments, announced today key changes to the leadership team
that will support OvaScience’s expanding global commercial operations.

OvaScience SM (NASDAQ: OVAS), a global life sciences company
focused on the discovery, development and commercialization of new
fertility treatments, announced today that the Company is hosting an
Investor Day on Wednesday, December 17, 2014 at the Benjamin Hotel in
New York from 8:00 a.m. to approximately 11:30 a.m. ET.

OvaScience SM (NASDAQ: OVAS), a global life sciences company
focused on the discovery, development and commercialization of new
fertility treatments, announced today that Company management will
participate in the Credit Suisse Global Healthcare One-on-One
Conference.

OvaScience SM (NASDAQ: OVAS), a global life sciences company
focused on the discovery, development and commercialization of new
fertility treatments, announced today that Company management will
present at the Leerink Global Healthcare Conference on Wednesday,
February 11, 2015 at 1:25 pm ET at the Waldorf Astoria hotel in New York
City.

OvaScience SM (NASDAQ: OVAS), a global life sciences company
focused on the discovery, development and commercialization of new
fertility treatments, announced today that Michelle Dipp, M.D., Ph.D.,
Chief Executive Officer of OvaScience, will present at the 33 rd
Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015
at 3:30 pm local time at the Westin St.

OvaScience SM (NASDAQ:OVAS), a global life sciences company
focused on the discovery, development and commercialization of new
fertility treatments, announced today that Company management will
present at the Oppenheimer 25 th Annual Healthcare Conference
on Thursday, December 11, 2014 at 2:10 pm ET at the Crowne Plaza Times
Square hotel in New York.

http://www.marketwire.com/library/MwGo/2015/1/6/11G029742/Hoffman_Chocolates_Logo-1122026321713.jpg
FORT LAUDERDALE, FL--(Marketwired - January 07, 2015) - Hoffman's Chocolates is pleased to announce that over 42,000 guests visited its 24 th Annual Winter Wonderland this holiday season making the spectacular attraction bigger and more festive than ever.

http://www.marketwire.com/library/MwGo/2015/2/3/11G032216/8986503714cc98f3_org-267875734.jpg
SHORT HILLS, NJ--(Marketwired - February 03, 2015) - Dun & Bradstreet (NYSE: DNB)
Dun & Bradstreet (NYSE: DNB), the world's leading source of commercial information and insight on businesses, today released its February 2015 U.S. Economic Health Tracker which provides a monthly, multi-dimensional perspective on the U.S. economy, including small business health, total job growth, and overall U.S. business health.

Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's
X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web"
award winner for five years running, X-Ray Interpreter goes under the hood of
your portfolio to provide a useful allocation, sector, and geographic analysis.
And you can discover how much of a stock you really own, individually and
through mutual funds, with Stock Intersection.

Portfolio Monitor
Get a clear view of your investments with personalized reports about
your portfolio. Receive monthly statements and generate reports
on-demand to help you stay on track to meet your investment goals.